TREATMENT OF SEXUAL DYSFUNCTION AND FOR IMPROVED SEXUAL QUALITY OF LIFE
Compositions and methods for treating sexual dysfunction and enhancing sexual satisfaction using topical application of alpha-1 adrenergic receptor agonists, muscarinic acetylcholine receptor agonists, nicotinic acetylcholine receptor agonists, and cholinesterase inhibitors are disclosed.
1 . A method of increasing sexual satisfaction in a female subject comprising applying a therapeutically effective amount of an active agent selected from the group consisting of muscarinic acetylcholine receptor agonists, nicotinic acetylcholine receptor agonists, and cholinesterase inhibitors topically to a nipple-areola complex of the female subject.
2 . The method of claim 1 , wherein the method results in the female subject having increased sexual self-esteem, increased self-perception of femininity, and/or increased self-esteem.
3 . The method of claim 1 , wherein the female subject has undergone breast surgery prior to application of the active agent and the surgery resulted in a reduction of nipple sensitivity.
4 . The method of claim 1 , wherein the active agent is applied in a sufficient amount to cause erection of the nipple or increased nipple sensitivity.
5 . The method of claim 1 , or wherein the active agent is a muscarinic acetylcholine receptor agonist selected from the group consisting of muscarinic acetylcholine receptor M 2 agonists and muscarinic acetylcholine receptor M 3 agonists.
6 . The method of claim 1 , or wherein the active agent is a muscarinic acetylcholine receptor agonist selected from the group consisting of NNC 11-1585, NNC 11-1607, pentylthio-TZTP, NNC 11-1314, xanomeline, sabcomeline, arecaidine propargyl ester, acetylcholine, arecoline, oxotremorine, McN-A-343, milameline, oxotremorine-M, methylfurmethide, bethanechol, carbachol, furtrethonium, methacholine, aceclidine, pilocarpine, and muscarine.
7 . The method of claim 1 , or wherein the active agent is a nicotinic acetylcholine receptor agonist selected from the group consisting of varenicline tartrate, galantamine hydrobromide, nicotine, carbachol, suxamethonium chloride (succinylcholine chloride), and epibatidine.
8 . The method of claim 1 , or wherein the active agent is a cholinesterase inhibitor selected from the group consisting of physostigmine, neostigmine, edrophonium, pyridostigmine, echotihiophate, ambenonium, demecarium, tacrine, donepezil, rivastigmine, galantamine, and pralidoxime.
9 . The method of claim 1 , wherein the female subject has reduced sensitivity at the nipple-areola complex before applying the active agent.
10 . A method of treating female sexual dysfunction, the method comprising applying a therapeutically effective amount of an active agent selected from the group consisting of muscarinic acetylcholine receptor agonists, nicotinic acetylcholine receptor agonists, and cholinesterase inhibitors topically to a nipple-areola complex of a female subject in need of such treatment.
11 . The method of claim 10 , wherein the composition is applied in a sufficient amount to cause erection of the nipple or increased nipple sensitivity.
12 . The method of claim 10 , wherein the active agent is a muscarinic acetylcholine receptor agonist selected from the group consisting of muscarinic acetylcholine receptor M 2 agonists and muscarinic acetylcholine receptor M 3 agonists.
13 . The method of claim 10 , wherein the active agent is a muscarinic acetylcholine receptor agonist selected from the group consisting of NNC 11-1585, NNC 11-1607, pentylthio-TZTP, NNC 11-1314, xanomeline, sabcomeline, arecaidine propargyl ester, acetylcholine, arecoline, oxotremorine, McN-A-343, milameline, oxotremorine-M, methylfurmethide, bethanechol, carbachol, furtrethonium, methacholine, aceclidine, pilocarpine, and muscarine.
14 . The method of claim 10 , wherein the active agent is a nicotinic acetylcholine receptor agonist selected from the group consisting of varenicline tartrate, galantamine hydrobromide, nicotine, carbachol, suxamethonium chloride (succinylcholine chloride), and epibatidine.
15 . The method of claim 10 , wherein the active agent is a cholinesterase inhibitor selected from the group consisting of physostigmine, neostigmine, edrophonium, pyridostigmine, echotihiophate, ambenonium, demecarium, tacrine, donepezil, rivastigmine, galantamine, and pralidoxime.
16 . The method of claim 10 , wherein the female sexual dysfunction is selected from the group consisting of female sexual arousal disorder (FSAD), female sexual interest/arousal disorder (FSIAD), female orgasmic disorder (FOD) and female hypoactive sexual desire disorder (FHSDD).
17 . A method of reducing or alleviating a symptom of female sexual dysfunction, the method comprising applying a therapeutically effective amount of an active agent selected from the group consisting of muscarinic acetylcholine receptor agonists, nicotinic acetylcholine receptor agonists, and cholinesterase inhibitors topically to a nipple-areola complex of a female subject in need of such treatment.
18 . The method of claim 17 , wherein the symptom of female sexual dysfunction is a symptom of female hypoactive sexual desire disorder (FHSDD), female sexual interest/arousal disorder (FSIAD), female orgasmic disorder (FOD) or female sexual arousal disorder (FSAD).
19 . The method of claim 17 , wherein the symptom of female sexual dysfunction is a symptom of female sexual interest/arousal disorder selected from the group consisting of (1) absent/reduced interest in sexual activity; (2) absent/reduced sexual/erotic thoughts or fantasies; (3) no/reduced initiation of sexual activity, and typically unreceptive to a partner's attempts to initiate; (4) absent/reduced sexual excitement/pleasure during sexual activity in almost all or all sexual encounters; (5) absent/reduced sexual interest/arousal in response to any internal or external sexual/erotic cues; and (6) absent/reduced genital or nongenital sensations during sexual activity in almost all or all sexual encounters.
20 . The method of claim 17 , wherein the active agent is applied in a sufficient amount to cause erection of the nipple or increased nipple sensitivity.
21 . The method of claim 17 , wherein the active agent is a muscarinic acetylcholine receptor agonist selected from the group consisting of muscarinic acetylcholine receptor M 2 agonists and muscarinic acetylcholine receptor M 3 agonists.
22 . The method of claim 17 , wherein the active agent is a muscarinic acetylcholine receptor agonist selected from the group consisting of NNC 11-1585, NNC 11-1607, pentylthio-TZTP, NNC 11-1314, xanomeline, sabcomeline, arecaidine propargyl ester, acetylcholine, arecoline, oxotremorine, McN-A-343, milameline, oxotremorine-M, methylfurmethide, bethanechol, carbachol, furtrethonium, methacholine, aceclidine, pilocarpine, and muscarine.
23 . The method of claim 17 , wherein the active agent is a nicotinic acetylcholine receptor agonist selected from the group consisting of varenicline tartrate, galantamine hydrobromide, nicotine, carbachol, suxamethonium chloride (succinylcholine chloride), and epibatidine.
24 . The method of claim 17 , wherein the active agent is a cholinesterase inhibitor selected from the group consisting of physostigmine, neostigmine, edrophonium, pyridostigmine, echotihiophate, ambenonium, demecarium, tacrine, donepezil, rivastigmine, galantamine, and pralidoxime.
25 . A method of causing erection of nipples, increasing nipple sensitivity, increasing duration of orgasm, reducing time to orgasm, and/or increasing oxytocin release related to sexual activity in a female subject comprising applying an effective amount of an active agent selected from the group consisting of muscarinic acetylcholine receptor agonists, nicotinic acetylcholine receptor agonists, and cholinesterase inhibitors topically to a nipple-areola complex of the female subject.
26 . The method of claim 25 , wherein the method is to increase nipple sensitivity in a female subject that had breast surgery.
27 . The method of claim 25 , wherein the method is to increase nipple sensitivity in a female subject who has not undergone breast surgery.
28 . A method for treating neuropathy in the nipple areola complex in a female subject comprising applying an effective amount of an active agent selected from the group consisting of muscarinic acetylcholine receptor agonists, nicotinic acetylcholine receptor agonists, and cholinesterase inhibitors topically to a nipple-areola complex of the female subject.
29 . The method of claim 25 , wherein the active agent is applied in a sufficient amount to cause erection of the nipple.
30 . The method of claim 25 , wherein the active agent is a muscarinic acetylcholine receptor agonist selected from the group consisting of muscarinic acetylcholine receptor M 2 agonists and muscarinic acetylcholine receptor M 3 agonists.
31 . The method of claim 25 , wherein the active agent is a muscarinic acetylcholine receptor agonist selected from the group consisting of NNC 11-1585, NNC 11-1607, pentylthio-TZTP, NNC 11-1314, xanomeline, sabcomeline, arecaidine propargyl ester, acetylcholine, arecoline, oxotremorine, McN-A-343, milameline, oxotremorine-M, methylfurmethide, bethanechol, carbachol, furtrethonium, methacholine, aceclidine, pilocarpine, and muscarine.
32 . The method of claim 25 , wherein the active agent is a nicotinic acetylcholine receptor agonist selected from the group consisting of varenicline tartrate, galantamine hydrobromide, nicotine, carbachol, suxamethonium chloride (succinylcholine chloride), and epibatidine.
33 . The method of claim 25 , wherein the active agent is a cholinesterase inhibitor selected from the group consisting of physostigmine, neostigmine, edrophonium, pyridostigmine, echotihiophate, ambenonium, demecarium, tacrine, donepezil, rivastigmine, galantamine, and pralidoxime.
34 . The method of one of claim 1 , wherein the composition is applied within one hour prior to a sexual activity.
35 . The method of one of claim 1 , wherein the subject is a premenopausal female.